To avoid muscle-related adverse events, choose statins carefully in patients receiving antiviral protease inhibitors
- First Online:
- Cite this article as:
- Adis Medical Writers Drugs Ther Perspect (2014) 30: 264. doi:10.1007/s40267-014-0122-8
- 56 Downloads
The appropriate statin to treat co-morbid dyslipidaemia requires careful selection in patient with hepatitis C virus (HCV) infection receiving HCV protease inhibitors (e.g. telaprevir and boceprevir), and those with HIV-1 infection receiving ritonavir- or cobicistat-boosted HIV protease inhibitors. HCV and boosted-HIV protease inhibitors can increase the plasma concentrations of certain statins, thereby increasing the risk of the potential for statin-related myopathy.